Temporary authorization for use: does the French patient access programme for unlicensed medicines impact market access after formal licensing?

Abstract:

BACKGROUND:To reach the French market, a new drug requires a marketing authorization (MA) and price and reimbursement agreements. These hurdles could delay access to new and promising drugs. Since 1992, French law authorizes the use of unlicensed drugs on an exceptional and temporary basis through a compassionate-use programme, known as Temporary Authorization for Use (ATU). This programme was implemented to improve early access to drugs under development or authorized abroad. However, it is suspected to be inflationary, bypassing public bodies in charge of health technology assessment (HTA) and of pricing. OBJECTIVE:The aim of this study is to observe the market access after the formal licensing of drugs that went through this compassionate-use programme. METHODS:We included all ATUs that received an MA between 1 January 2005 and 30 June 2010. We first examined market access delays from these drugs using the standard administrative path. We positioned this result in relation to launch delays observed in France (for all outpatient drugs) and in other major European markets. Second, we assessed the bargaining power of a hospital purchaser after those drugs had obtained an MA by calculating the price growth rate after the approval. RESULTS:During the study period, 77 ATUs were formally licensed. The study concluded that, from the patient's perspective, licensing and public bodies' review time was shortened by a combined total of 36 months. The projected 11-month review time of public bodies may be longer than delays usually observed for outpatient drugs. Nonetheless, the study revealed significant benefits for French patient access based on comparable processing to launch time with those of other European countries with tight price control policies. In return, a 12 % premium, on average, is paid to pharmaceutical companies while drugs are under this status (sub-analysis on 56 drugs). CONCLUSIONS:In many instances, the ATU programme responds to a public health need by accelerating the availability of new drugs even though this study suggests an impact of the programme on the market access of these drugs for which the standard administrative path is longer than usual. In addition, pharmaceutical companies seem to market compassionate-use drugs with a presumed benefit/risk ratio at a price that guarantees a margin for future negotiation.

journal_name

Pharmacoeconomics

journal_title

PharmacoEconomics

authors

Degrassat-Théas A,Paubel P,Parent de Curzon O,Le Pen C,Sinègre M

doi

10.1007/s40273-013-0039-4

subject

Has Abstract

pub_date

2013-04-01 00:00:00

pages

335-43

issue

4

eissn

1170-7690

issn

1179-2027

journal_volume

31

pub_type

杂志文章
  • Oral ciprofloxacin: a pharmacoeconomic evaluation of its use in the treatment of serious infections.

    abstract::The broad spectrum of antibacterial activity and favourable pharmacokinetic profile of ciprofloxacin permit oral treatment of many serious infections which have traditionally necessitated parenteral antibacterial therapy. This has been demonstrated in comparative studies, in which ciprofloxacin was as effective and w...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.2165/00019053-199303050-00007

    authors: Balfour JA,Faulds D

    更新日期:1993-05-01 00:00:00

  • Pharmacoeconomics and health policy. Current applications and prospects for the future.

    abstract::The use of pharmacoeconomic tools has grown dramatically in the past decade as provision of healthcare throughout the industrialised world has required increased cost consciousness. However, pharmacoeconomic analysis has not yet been fully exploited as a conceptual underpinning for public or private health policy deci...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-199916050-00001

    authors: Greenberg PE,Arcelus A,Birnbaum HG,Cremieux PY,LeLorier J,Ouellette P,Slavin MB

    更新日期:1999-11-01 00:00:00

  • Value-based approaches to healthcare systems and pharmacoeconomics requirements in Asia: South Korea, Taiwan, Thailand and Japan.

    abstract::Asian healthcare systems are very diverse, representing cultures, political systems and economies from more than 30 countries with varying histories. Despite the diversity in the region, there has been enormous growth in health economics and outcomes research since the beginning of the 21st century. Whilst Japan has s...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/11538360-000000000-00000

    authors: Kamae I

    更新日期:2010-01-01 00:00:00

  • Barrett's oesophagus: a review of costs of the illness.

    abstract::Barrett's oesophagus is a premalignant complication that occurs in approximately 10% of patients with gastro-oesophageal reflux disease (GORD). In patients with Barrett's oesophagus, the risk of adenocarcinoma of the oesophagus approaches 0.5% per patient-years. Therefore, practice guidelines have been developed that ...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.2165/00019053-200119100-00003

    authors: Arguedas MR,Eloubeidi MA

    更新日期:2001-01-01 00:00:00

  • Treatment costs and quality of life with granulocyte-macrophage colony-stimulating factor in patients with antineoplastic therapy-related febrile neutropenia. Results of a randomised placebo-controlled trial.

    abstract::This study examined the costs of treatment of, and quality of life in, patients with antineoplastic therapy-induced neutropenic fever who were treated with antibacterials, with or without granulocyte-macrophage colony-stimulating factor (GM-CSF). Patients with haematological malignancies (n = 47) or solid tumours (n =...

    journal_title:PharmacoEconomics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00019053-199712030-00007

    authors: Uyl-de Groot CA,Vellenga E,de Vries EG,Löwenberg B,Stoter GJ,Rutten FF

    更新日期:1997-09-01 00:00:00

  • Lopinavir/ritonavir versus darunavir plus ritonavir for HIV infection: a cost-effectiveness analysis for the United States.

    abstract:BACKGROUND:The ARTEMIS trial compared first-line antiretroviral therapy (ART) with lopinavir/ritonavir (LPV/r) to darunavir plus ritonavir (DRV + RTV) for HIV-1-infected subjects. In order to fully assess the implications of this study, economic modelling extrapolating over a longer term is required. OBJECTIVE:The aim...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.1007/s40273-013-0048-3

    authors: Simpson KN,Pei PP,Möller J,Baran RW,Dietz B,Woodward W,Migliaccio-Walle K,Caro JJ

    更新日期:2013-05-01 00:00:00

  • The Application and Implications of Novel Deterministic Sensitivity Analysis Methods.

    abstract::Deterministic sensitivity analyses (DSA) remain important to interpret the effect of uncertainties in individual parameters on results of cost-effectiveness analyses. Classic DSA methodologies may lead to wrong conclusions due to a lack of or misleading information regarding marginal effects, non-linearity, likelihood...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.1007/s40273-020-00979-3

    authors: Vreman RA,Geenen JW,Knies S,Mantel-Teeuwisse AK,Leufkens HGM,Goettsch WG

    更新日期:2021-01-01 00:00:00

  • Enoxaparin. A pharmacoeconomic appraisal of its use in thromboembolic prophylaxis after total hip arthroplasty.

    abstract::Total hip arthroplasty (THA) is a major orthopaedic procedure with a high risk of postoperative thromboembolism. Increasing demand for this type of surgery, together with its high cost, has led to examination of means by which the cost of THA may be minimised. Current clinical opinion favours the use of suitable pharm...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-199610020-00009

    authors: Dunn CJ,Goa KL

    更新日期:1996-08-01 00:00:00

  • Acknowledging patient heterogeneity in economic evaluation : a systematic literature review.

    abstract:BACKGROUND AND OBJECTIVE:Patient heterogeneity is the part of variability that can be explained by certain patient characteristics (e.g. age, disease stage). Population reimbursement decisions that acknowledge patient heterogeneity could potentially save money and increase population health. To date, however, economic ...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.1007/s40273-012-0015-4

    authors: Grutters JP,Sculpher M,Briggs AH,Severens JL,Candel MJ,Stahl JE,De Ruysscher D,Boer A,Ramaekers BL,Joore MA

    更新日期:2013-02-01 00:00:00

  • The Pharmacoeconomic Evaluation Process in Ireland.

    abstract:BACKGROUND:In Ireland, all new drugs are considered for a formal pharmacoeconomic evaluation (PE) prior to a reimbursement decision. All evaluations are conducted by the National Centre for Pharmacoeconomics (NCPE). The objectives of this study were to describe the evaluation process and to examine the movement of drug...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.1007/s40273-016-0437-5

    authors: McCullagh L,Barry M

    更新日期:2016-12-01 00:00:00

  • Financing Drug Innovation in the US: Current Framework and Emerging Challenges.

    abstract::The current US drug innovation financing framework rests on the notion that a defined period of marketing exclusivity combined with the expectation of reimbursement for clinically valuable, cost-effective therapies, followed by vigorous price competition from generic drugs and biosimilars ensures a sufficient return o...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.1007/s40273-020-00926-2

    authors: Cutler D,Kirson N,Long G

    更新日期:2020-09-01 00:00:00

  • The role of models within economic analysis: focus on type 2 diabetes mellitus.

    abstract::Economic analysis of healthcare interventions is increasingly reliant on decision models to estimate the long-term costs and benefits of new therapies. Models permit analysts to take short-term clinical data to forecast long-term costs and benefits. Models should follow certain basic principles and can be appraised in...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.2165/00019053-200220001-00002

    authors: Coyle D,Lee KM,O'Brien BJ

    更新日期:2002-01-01 00:00:00

  • Discounting in cost-utility analysis of healthcare interventions: reassessing current practice.

    abstract::Cost-utility analysis (CUA) is a technique that can potentially be used as a guide to allocating healthcare resources so as to obtain the maximum health benefits possible under a given budget constraint. However, it is not clear that current practice captures societal preferences regarding health benefits. In analyses...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-200321020-00001

    authors: Cohen BJ

    更新日期:2003-01-01 00:00:00

  • Parent-proxy EQ-5D ratings of children with attention-deficit hyperactivity disorder in the US and the UK.

    abstract:BACKGROUND:The symptoms of attention-deficit hyperactivity disorder (ADHD) are associated with impairment in multiple domains of health-related quality of life (HR-QOL). HR-QOL of children with ADHD has been assessed by relatively long multidimensional questionnaires. A review of the literature found no studies using t...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-200523080-00004

    authors: Matza LS,Secnik K,Mannix S,Sallee FR

    更新日期:2005-01-01 00:00:00

  • Cost-minimisation study of dorzolamide versus brinzolamide in the treatment of ocular hypertension and primary open-angle glaucoma: in four European countries.

    abstract:OBJECTIVE:Cost is an issue when prescribing two drugs with equivalent efficacy. We compared the direct medical costs of topical brinzolamide 1% (twice a day or three times daily) with topical dorzolamide 2% (twice a day or three times daily) in France, Italy, Portugal and Spain in patients with ocular hypertension or p...

    journal_title:PharmacoEconomics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00019053-200321030-00005

    authors: Rouland JF,Le Pen C,Gouveia Pinto C,Berto P,Berdeaux G

    更新日期:2003-01-01 00:00:00

  • The humanistic burden of head and neck cancer: a systematic literature review.

    abstract:BACKGROUND:Head and neck cancer (HNC) and its treatment can affect communication, nutrition, and physical appearance, and the global impact of this disease on patients' quality of life may be substantial. OBJECTIVE:The aim of this systematic literature review was to describe the impact of HNC and its treatment on the ...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.1007/s40273-014-0199-x

    authors: Wissinger E,Griebsch I,Lungershausen J,Byrnes M,Travers K,Pashos CL

    更新日期:2014-12-01 00:00:00

  • Economic evaluation of levetiracetam as an add-on therapy in patients with refractory epilepsy.

    abstract:OBJECTIVES:This study provides the results of a cost-effectiveness analysis of levetiracetam as an adjunctive treatment for refractory epilepsy from the Canadian Ministry of Health perspective. The main objective is to estimate the expected cost-effectiveness ratio expressed as the incremental cost per seizure-free day...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-200523050-00008

    authors: Blais L,Sheehy O,St-Hilaire JM,Bernier G,Godfroid P,LeLorier JJ

    更新日期:2005-01-01 00:00:00

  • Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK.

    abstract:INTRODUCTION:The objective of this study was to evaluate the potential economic implications of using etoricoxib versus non-selective NSAID alternatives in the treatment of patients with osteoarthritis (OA) or rheumatoid arthritis (RA) in the UK. STUDY DESIGN:Decision-analytical modelling was used to calculate the exp...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-200422100-00003

    authors: Moore A,Phillips C,Hunsche E,Pellissier J,Crespi S

    更新日期:2004-01-01 00:00:00

  • Applying recent findings to clinical care in type II diabetes.

    abstract::There is a global perspective to the economic consequences of diabetes, which is illustrated in the many publications now being produced on this subject. Because of the higher prevalence of type II diabetes, its impact is greater than that of type I diabetes in both developed and developing countries (but particularly...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.2165/00019053-199500081-00017

    authors: Williams R

    更新日期:1995-01-01 00:00:00

  • Generic clozapine: a cost-saving alternative to brand name clozapine?

    abstract::As a consequence of its prevalence, early onset and chronicity, schizophrenia imposes clinical and economic impediments to healthcare practitioners and society alike. Among the many antipsychotics available to treat the symptoms of this devastating illness, clozapine has emerged and differentiated itself from the othe...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.2165/00019053-200321010-00001

    authors: Tse G,Thompson D,Procyshyn RM

    更新日期:2003-01-01 00:00:00

  • The MAPS Reporting Statement for Studies Mapping onto Generic Preference-Based Outcome Measures: Explanation and Elaboration.

    abstract:BACKGROUND:The process of "mapping" is increasingly being used to predict health utilities, for application within health economic evaluations, using data on other indicators or measures of health. Guidance for the reporting of mapping studies is currently lacking. OBJECTIVE:The overall objective of this research was ...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.1007/s40273-015-0312-9

    authors: Petrou S,Rivero-Arias O,Dakin H,Longworth L,Oppe M,Froud R,Gray A

    更新日期:2015-10-01 00:00:00

  • Correction to: Calculating and Interpreting ICERs and Net Benefit.

    abstract::The original article can be found online. ...

    journal_title:PharmacoEconomics

    pub_type: 已发布勘误

    doi:10.1007/s40273-020-00950-2

    authors: Paulden M

    更新日期:2020-10-01 00:00:00

  • How Qualitative Methods Can be Used to Inform Model Development.

    abstract::Decision-analytic models play a key role in informing healthcare resource allocation decisions. However, there are ongoing concerns with the credibility of models. Modelling methods guidance can encourage good practice within model development, but its value is dependent on its ability to address the areas that modell...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.1007/s40273-017-0499-z

    authors: Husbands S,Jowett S,Barton P,Coast J

    更新日期:2017-06-01 00:00:00

  • Per-patient-per-month drug costs in Medicare Part D protected classes.

    abstract:OBJECTIVE:The objective of this study was to estimate the per-patient-per-month (PPPM) costs of medications in the six Medicare Part D protected classes based on findings among Medicare and dual eligible beneficiaries with drug coverage before the enactment of the benefit. DESIGN:Data were from the Thomson Medstat Mar...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-200624003-00007

    authors: Mucha L,Masia NA,Axelsen KJ

    更新日期:2006-01-01 00:00:00

  • The applicability and generalizability of findings from clinical trials for health-policy decisions.

    abstract::Randomized controlled trials provide unbiased estimates of treatment effect through reducing the attribution of observed differences in outcome to the play of chance or the treatment of interest. Issues in the design of randomized trials may lead to a dilution or magnification of treatment effect when compared with cl...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-200927010-00002

    authors: Freemantle N,Hessel F

    更新日期:2009-01-01 00:00:00

  • Conducting discrete choice experiments to inform healthcare decision making: a user's guide.

    abstract::Discrete choice experiments (DCEs) are regularly used in health economics to elicit preferences for healthcare products and programmes. There is growing recognition that DCEs can provide more than information on preferences and, in particular, they have the potential to contribute more directly to outcome measurement ...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-200826080-00004

    authors: Lancsar E,Louviere J

    更新日期:2008-01-01 00:00:00

  • Oral antiplatelet therapy in secondary prevention of cardiovascular events: an assessment from the payer's perspective.

    abstract:BACKGROUND:A wide variety of oral antiplatelet trials have been carried out, and a large number of cost-effectiveness estimates based on them have been published. OBJECTIVE:To assess the cost effectiveness of oral antiplatelet treatments in the prevention of cardiovascular events. METHODS:A comprehensive literature s...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,meta分析,评审

    doi:10.2165/00019053-200725120-00007

    authors: Heeg B,Damen J,Van Hout B

    更新日期:2007-01-01 00:00:00

  • Informing a Cost-Effectiveness Threshold for Health Technology Assessment in China: A Marginal Productivity Approach.

    abstract:BACKGROUND:Health technology assessment has been increasingly used in China, having been legally mandated in 2019, to inform reimbursement decisions and price negotiations between the National Healthcare Security Administration and pharmaceutical companies around the price of new pharmaceuticals. The criteria currently...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.1007/s40273-020-00954-y

    authors: Ochalek J,Wang H,Gu Y,Lomas J,Cutler H,Jin C

    更新日期:2020-12-01 00:00:00

  • Simulating Progression-Free and Overall Survival for First-Line Doublet Chemotherapy With or Without Bevacizumab in Metastatic Colorectal Cancer Patients Based on Real-World Registry Data.

    abstract:BACKGROUND:Simulation models utilizing real-world data have potential to optimize treatment sequencing strategies for specific patient subpopulations, including when conducting clinical trials is not feasible. We aimed to develop a simulation model to estimate progression-free survival (PFS) and overall survival for fi...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.1007/s40273-020-00951-1

    authors: Degeling K,Wong HL,Koffijberg H,Jalali A,Shapiro J,Kosmider S,Wong R,Lee B,Burge M,Tie J,Yip D,Nott L,Khattak A,Lim S,Caird S,Gibbs P,IJzerman M

    更新日期:2020-11-01 00:00:00

  • Quality of life following a change in therapy for diabetes mellitus.

    abstract:OBJECTIVE:The study objective was to evaluate and compare quality-of-life (QOL) parameters between patients with type 2 (non-insulin-dependent) diabetes mellitus who changed therapy from an oral hypoglycaemic agent (OHA) to insulin and those who remained on an OHA. DESIGN:The World Health Organization Quality of Life ...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-199814020-00008

    authors: Pibernik-Okanović M,Szabo S,Metelko Z

    更新日期:1998-08-01 00:00:00